1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Cian Healthcare Limited

Cian Healthcare Limited

CHCL.BO
Cian Healthcare LimitedIN flagBombay Stock Exchange
5.01
INR
- -
- -
125.25MMarket Cap
Cian Healthcare Limited
CHCL.BO
(Bombay Stock Exchange)

Recent

price

5.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
FRC
291.3
323.13
370.77
389.64
355.94
404.81
453.35
399.05
360.33
179.61
- -
Revenue per Share
8.56
13.96
24.99
4.09
-23.62
0.29
-32.22
11.81
4.96
-151.5
- -
Basic EPS, GAAP
56.73
7.97
30.04
42.86
-167.82
24.5
-50.88
20.46
62.99
118.66
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
46.01
59.97
89.27
116.72
128.1
128.26
145.52
145.42
145.99
145.77
- -
Book Value per Share
65.28
79.93
110.01
135.42
332.33
319.79
322.86
334.45
340.71
188.7
- -
Tangible Book Value per Share
2
2
2
2
2
2
2
2
2
2
- -
Basic Weighted Avg Shares
467
518
594
624
571
737
779
686
617
308
283
Sales/Revenue/Turnover
12.13
15.73
18.56
9.48
5.5
11.86
0.36
11.14
9.4
-36.02
-38.3
Operating Margin (%)
19
19
14
24
44
35
43
54
55
44
39
Depreciation Expense
14
22
40
7
-38
1
-55
20
8
-260
-233
Net Income, GAAP
36.49
27.36
23.86
30.35
- -
92.27
- -
- -
- -
- -
- -
Effective Tax Rate (%)
2.94
4.32
6.74
1.05
-6.63
0.07
-7.11
2.96
1.38
-84.35
-82.31
Profit Margin (%)
25
64
107
75
58
56
95
90
56
-437
-63
Working Capital
204
240
246
229
458
376
381
294
275
69
202
LT Debt
108
130
177
217
582
582
555
575
583
324
85
Total Equity
- -
11.95
13.45
5.89
- -
0.52
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
12.99
14.2
6.67
- -
0.68
- -
- -
- -
- -
- -
Return on Capital (%)
- -
26.34
33.49
3.97
-19.3
0.24
-22.89
8.12
3.39
-103.93
-93.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.95%
-23.56%
-73.62%
Free Cash Flow
-51.89%
-28.79%
-3.22%
Net Income, GAAP
-1,460.86%
-2,777.5%
-10.34%
Sales/Revenue/Turnover
-2.32%
-14.91%
-8.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
617
2025
- -
- -
- -
- -
308
2026
- -
- -
- -
- -
283

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.96
2025
- -
- -
- -
- -
-151.5
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Doseology Sciences Inc. (MOOD.CN)
Cullinan Therapeutics, Inc. (CGEM)
New Nordic Healthbrands AB (NNH.ST)
Vivanza Biosciences Limited (VIVANZA.BO)
Sotac Pharmaceuticals Ltd. (SOTAC.NS)
CannAmerica Brands Corp. (CNNXF)
Business
Cian Healthcare Limited (CHCL.BO) is an India-based pharmaceutical company engaged in the manufacturing and marketing of generic and branded formulations across various therapeutic segments. The company offers a diverse portfolio of products including tablets, capsules, injectables, ointments, and powders; key categories encompass anti-infectives, analgesics, anti-diabetics, cardiovascular drugs, gastro-intestinal treatments, and nutraceuticals, marketed under brands such as Cianpro, Ciangrow, and Cianfit. It primarily serves retail pharmacies, hospitals, and institutional customers in India, with distribution networks spanning major regions including Maharashtra, Gujarat, Uttar Pradesh, and emerging markets in South India. Founded in 2015 and headquartered in Mumbai, India, Cian Healthcare operates manufacturing facilities compliant with WHO-GMP standards, focusing on affordable healthcare solutions for chronic and acute conditions. The company targets middle-income consumers and government tenders, emphasizing quality generics and value-added services like contract manufacturing. Its business segments include domestic formulations, exports to select Asian and African countries, and a growing nutraceutical division. In recent developments, Cian Healthcare expanded its product pipeline with the launch of five new anti-diabetic combinations and two oncology injectables in 2024, strengthening its chronic therapy portfolio. The company secured a strategic distribution partnership with a leading South Indian pharma distributor in early 2025 to boost market penetration in Tamil Nadu and Karnataka. Additionally, it raised INR 50 crore through a preferential allotment in Q3 2025 to fund capacity expansion and R&D for complex generics.